How can monoclonal antibodies be harnessed against neglected tropical diseases and other infectious diseases?

被引:23
作者
Laustsen, Andreas H. [1 ]
机构
[1] Tech Univ Denmark, Dept Biotechnol & Biomed, Lyngby, Denmark
关键词
Neglected tropical diseases; monoclonal antibodies; infectious diseases; antibody discovery; affordable biotherapeutics; tropical pharmacology; snakebite envenoming; animal envenomings; parasitic diseases; bacterial infections; POSTEXPOSURE PROPHYLAXIS; THERAPEUTIC ANTIBODIES; PARASITES EVADE; IN-VITRO; NEUTRALIZATION; TOXIN; ANTIGEN; ANAPHYLAXIS; PROTECTION; DIAGNOSIS;
D O I
10.1080/17460441.2019.1646723
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Monoclonal antibody-based therapies now represent the single-largest class of molecules undergoing clinical investigation. Although a handful of different monoclonal antibodies have been clinically approved for bacterial and viral indications, including rabies, therapies based on monoclonal antibodies are yet to fully enter the fields of neglected tropical diseases and other infectious diseases. Areas covered: This review presents the current state-of-the-art in the development and use of monoclonal antibodies against neglected tropical diseases and other infectious diseases, including viral, bacterial, and parasitic infections, as well as envenomings by animal bites and stings. Additionally, a short section on mushroom poisonings is included. Key challenges for developing antibody-based therapeutics are discussed for each of these fields. Expert opinion: Neglected tropical diseases and other infectious diseases represent a golden opportunity for academics and technology developers for advancing our scientific capabilities within the understanding and design of antibody cross-reactivity, use of oligoclonal antibody mixtures for multi-target neutralization, novel immunization methodologies, targeting of evasive pathogens, and development of fundamentally novel therapeutic mechanisms of action. Furthermore, a huge humanitarian and societal impact is to gain by exploiting antibody technologies for the development of biotherapies against diseases, for which current treatment options are suboptimal or non-existent.
引用
收藏
页码:1103 / 1112
页数:10
相关论文
共 110 条
  • [61] Food Animals and Antimicrobials: Impacts on Human Health
    Marshall, Bonnie M.
    Levy, Stuart B.
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 2011, 24 (04) : 718 - +
  • [62] Monoclonal Antibodies for Emerging Infectious Diseases - Borrowing from History
    Marston, Hilary D.
    Paules, Catharine I.
    Fauci, Anthony S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (16) : 1469 - 1472
  • [63] Recombinant human monoclonal antibodies to Ebola virus
    Maruyama, T
    Parren, PWHI
    Sanchez, A
    Rensink, I
    Rodriguez, LL
    Khan, AS
    Peters, CJ
    Burton, DR
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1999, 179 : S235 - S239
  • [64] Development of camelid single chain antibodies against Shiga toxin type 2 (Stx2) with therapeutic potential against Hemolytic Uremic Syndrome (HUS)
    Mejias, Maria P.
    Hiriart, Yanina
    Lauche, Constanza
    Fernandez-Brando, Romina J.
    Pardo, Romina
    Bruballa, Andrea
    Ramos, Maria V.
    Goldbaum, Fernando A.
    Palermo, Marina S.
    Zylberman, Vanesa
    [J]. SCIENTIFIC REPORTS, 2016, 6
  • [65] Raxibacumab for the Treatment of Inhalational Anthrax.
    Migone, Thi-Sau
    Subramanian, G. Mani
    Zhong, John
    Healey, Letha M.
    Corey, Al
    Devalaraja, Matt
    Lo, Larry
    Ullrich, Stephen
    Zimmerman, Janelle
    Chen, Andrew
    Lewis, Maggie
    Meister, Gabriel
    Gillum, Karen
    Sanford, Daniel
    Mott, Jason
    Bolmer, Sally D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (02) : 135 - 144
  • [66] Structural insight in the inhibition of adherence of F4 fimbriae producing enterotoxigenic Escherichia coli by llama single domain antibodies
    Moonens, Kristof
    Van den Broeck, Imke
    Okello, Emmanuel
    Pardon, Els
    De Kerpel, Maia
    Remaut, Han
    De Greve, Henri
    [J]. VETERINARY RESEARCH, 2015, 46
  • [67] Nanobody Mediated Inhibition of Attachment of F18 Fimbriae Expressing Escherichia coli
    Moonens, Kristof
    De Kerpel, Maia
    Coddens, Annelies
    Cox, Eric
    Pardon, Els
    Remaut, Han
    De Greve, Henri
    [J]. PLOS ONE, 2014, 9 (12):
  • [68] Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection
    Navalkele, Bhagyashri D.
    Chopra, Teena
    [J]. BIOLOGICS-TARGETS & THERAPY, 2018, 12 : 11 - 21
  • [69] Nejad-Moghaddam Amir, 2009, Iranian Biomedical Journal, V13, P245
  • [70] Antigen detection assay with parasite specific monoclonal antibodies for diagnosis of lymphatic filariasis
    Pandey, Vivek
    Madhumathi, Jayaprakasam
    Karande, Anjali A.
    Kaliraj, Perumal
    [J]. CLINICA CHIMICA ACTA, 2011, 412 (19-20) : 1867 - 1873